| R&D investment is the source of enterprise technology innovation and power,for the pharmaceutical industry is more important. Research on R&D investment in the pharmaceutical industry will help provide decision-making reference for business decision-makers and provide decision-making basis for improving business performance.Based on the theory of R&D investment and technological innovation, this paper analyzes the current situation of research at home and abroad in recent years.At present, the research on R&D investment, technological innovation and enterprise performance in the pharmaceutical industry mainly has the following problems: (1)The lack of sample enterprises, the statistical time span is short; (2) Only the pharmaceutical industry R&D investment, technological innovation and corporate performance related research, and did not study the R&D investment in the enterprise is how to put into what aspects and R&D investment and performance indicators output efficiency.In order to solve the above problems, this paper first enlarges the number of research samples and increases the number of years of research, and then combines empirical research and case analysis. The specific research contents are as follows:(1) Empirical research: This paper takes 197 pharmaceutical companies listed in Shanghai and Shenzhen as the research object, and summarizes the research variables such as R&D investment cost, patent quantity and net profit in 2008 and 2015. The R&D input cost is a measure of R&D input; the number of patents is used as a measure of technological innovation, and the net profit is used as the performance index. The results show that there is a significant positive correlation between the R&D investment cost of the pharmaceutical industry and the number of selected technical innovation indicators, and the R&D investment cost is only positively correlated with the net profit of the firm’s performance indicators.(2) Case study: On the basis of empirical analysis, this paper chooses Harbin Pharmaceutical shares to carry out case studies, taking the number of patents of technological innovation indicators and the net profit of enterprise performance indicators as the main research variables. Mainly from the following two aspects: on the one hand to verify the results of empirical research; the other hand, the study of Harbin Pharmaceutical shares R&D costs into what aspects, how to invest and R&D investment after the output efficiency and other issues. The results show that the R&D investment of Harbin Pharmaceutical shares is mainly concentrated in the biotechnology products. The most efficient technological innovation of R&D input and output is S001GR project for hepatitis B drug research, R&D investment in the production of the highest efficiency of the nutritional supplements.Finally, according to the research results of this paper, a series of suggestions are put forward from the perspective of macroscopic pharmaceutical industry and the specific Harbin Pharmaceutical Company. |
PDF Full Text Request